Lu isn’t alone in his belief that CRISPR’s editing technology holds the key to unlocking cures for some of the deadliest diseases facing humanity. Senti Biosciences has launched with $53m in funding, setting its "world-class interdisciplinary team" to develop gene therapies for diseases including cancer. Founded by veteran synthetic biologist Tim Lu and boasting a host of eminent scientists, Senti will use CRISPR gene-editing technology to create new programmable cells capable of performing specific functions, beginning with targeting cancerous tumours. The company is also working on the development of drugs that can target cancer cells.
Senti Biosciences has launched with $53m in funding, setting its "world-class interdisciplinary team" to develop gene therapies for diseases including cancer. Founded by veteran synthetic biologist Tim Lu and boasting a host of eminent scientists, Senti will use CRISPR gene-editing technology to create new programmable cells capable of performing specific functions, beginning with targeting cancerous tumours. The company is also working on the development of drugs that can target cancer cells.